Catching Up on Schizophrenia Natural History and Neurobiology
暂无分享,去创建一个
[1] Pat Levitt,et al. Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.
[2] M. Laruelle,et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia , 2000, Biological Psychiatry.
[3] J. Lieberman,et al. Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia , 2000, Biological Psychiatry.
[4] E G Jones,et al. Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[5] David A. Lewis,et al. Is There a Neuropathology of Schizophrenia? Recent Findings Converge on Altered Thalamic-Prefrontal Cortical Connectivity , 2000 .
[6] D. German,et al. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia , 2000, Biological Psychiatry.
[7] W. Honer,et al. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. , 2000, Science.
[8] Yogesh K. Dwivedi,et al. 223. Reelin and GAD67 downregulation and psychosis vulnerability , 2000, Biological Psychiatry.
[9] S. Kapur,et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.
[10] Marc Laruelle,et al. The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies , 2000, Brain Research Reviews.
[11] A. Sampson,et al. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. , 2000, Archives of general psychiatry.
[12] M. Tsuang. Schizophrenia: genes and environment , 2000, Biological Psychiatry.
[13] A. Pulver. Search for schizophrenia susceptibility genes , 2000, Biological Psychiatry.
[14] J A Frank,et al. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. , 2000, The American journal of psychiatry.
[15] D. Lewis,et al. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. , 2000, Archives of general psychiatry.
[16] J. Pierri,et al. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. , 1999, The American journal of psychiatry.
[17] E. Bromet,et al. Epidemiology and natural history of schizophrenia , 1999, Biological Psychiatry.
[18] A. Sampson,et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. , 1999, The American journal of psychiatry.
[19] Jeffrey A Lieberman,et al. Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective , 1999, Biological Psychiatry.
[20] A Reichenberg,et al. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. , 1999, The American journal of psychiatry.
[21] Marc G Caron,et al. Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia , 1999, Cell.
[22] W. Honer,et al. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness , 1999, Neuroscience.
[23] M. Laruelle,et al. Increased dopamine transmission in schizophrenia: relationship to illness phases , 1999, Biological Psychiatry.
[24] J. Rapoport,et al. Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. , 1999, Archives of general psychiatry.
[25] N. Makris,et al. Cortical abnormalities in schizophrenia identified by structural magnetic resonance imaging. , 1999, Archives of general psychiatry.
[26] R. McCarley,et al. MRI anatomy of schizophrenia , 1999, Biological Psychiatry.
[27] J. Lieberman,et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. , 1999, The American journal of psychiatry.
[28] Paul J. Harrison. The neuropathology of schizophrenia , 2008 .
[29] R. Roth,et al. The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia , 1999, Neuropsychopharmacology.
[30] J. Lieberman,et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. , 1999, Archives of general psychiatry.
[31] P. Andersen,et al. Effects of family history and place and season of birth on the risk of schizophrenia. , 1999, The New England journal of medicine.
[32] D. Weinberger,et al. Cell biology of the hippocampal formation in schizophrenia , 1999, Biological Psychiatry.
[33] P. Goldman-Rakic,et al. The reduced neuropil hypothesis: a circuit based model of schizophrenia , 1999, Biological Psychiatry.
[34] Philip D. Harvey,et al. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients , 1999, Biological Psychiatry.
[35] W Q Sturner,et al. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for ‘hypofrontality’ , 1999, Molecular Psychiatry.
[36] R. Gur,et al. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. , 1998, The American journal of psychiatry.
[37] J A Frank,et al. Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. , 1998, The American journal of psychiatry.
[38] S. Hirsch,et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia , 1998, Journal of neurology, neurosurgery, and psychiatry.
[39] B. Moghaddam,et al. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.
[40] Lina Shihabuddin,et al. Ventricular Enlargement in Poor-Outcome Schizophrenia , 1998, Biological Psychiatry.
[41] A. Malhotra,et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach , 1998, Synapse.
[42] N. Alpert,et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia , 1998, Nature Neuroscience.
[43] Ron Kikinis,et al. Volumetric Evaluation of the Thalamus in Schizophrenic Male Patients Using Magnetic Resonance Imaging , 1998, Biological Psychiatry.
[44] P. Goldman-Rakic,et al. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. , 1998, Archives of general psychiatry.
[45] P. Sham,et al. Obstetric complications and familial morbid risk of psychiatric disorders. , 1998, American journal of medical genetics.
[46] D. Weinberger,et al. Schizophrenia as a developmental disorder of the cerebral cortex , 1998, Current Opinion in Neurobiology.
[47] Tyrone D. Cannon,et al. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. , 1998, Archives of general psychiatry.
[48] A. Riecher-Rössler,et al. Causes and consequences of the gender difference in age at onset of schizophrenia. , 1998, Schizophrenia bulletin.
[49] R. Yolken,et al. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature , 1997, Schizophrenia Research.
[50] L. Glantz,et al. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. , 1997, Archives of general psychiatry.
[51] Jeffrey A Lieberman,et al. Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity , 1997, Neuropsychopharmacology.
[52] D. Weinberger,et al. Cognitive function in schizophrenia , 1997, International clinical psychopharmacology.
[53] Paul J. Harrison,et al. Size, shape, and orientation of neurons in the left and right hippocampus: investigation of normal asymmetries and alterations in schizophrenia. , 1997, The American journal of psychiatry.
[54] D. Lewis,et al. Development of the Prefrontal Cortex during Adolescence: Insights into Vulnerable Neural Circuits in Schizophrenia , 1997, Neuropsychopharmacology.
[55] A. Malhotra,et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[56] M. Iyo,et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.
[57] P. Jones. The early origins of schizophrenia. , 1997, British medical bulletin.
[58] J. Lieberman,et al. The evaluation and treatment of first-episode psychosis. , 1997, Schizophrenia bulletin.
[59] P. Goldman-Rakic,et al. Functional and anatomical aspects of prefrontal pathology in schizophrenia. , 1997, Schizophrenia bulletin.
[60] J. Hietala,et al. Dopamine in schizophrenia. , 1996, Annals of medicine.
[61] N. Perrone-Bizzozero,et al. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[62] J. Krystal,et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[63] J C Rajapakse,et al. Brain anatomic magnetic resonance imaging in childhood-onset schizophrenia. , 1996, Archives of general psychiatry.
[64] S. Taylor,et al. Cerebral blood flow activation and functional lesions in schizophrenia , 1996, Schizophrenia Research.
[65] Streichenwein Sm,et al. Am J Psychiatry , 1996 .
[66] Michael F. Green,et al. What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.
[67] J. Lieberman,et al. Psychobiologic Correlates of Treatment Response in Schizophrenia , 1996, Neuropsychopharmacology.
[68] R. Mark Wightman,et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.
[69] M S Buchsbaum,et al. PET and MRI of the thalamus in never-medicated patients with schizophrenia. , 1996, The American journal of psychiatry.
[70] T. McGlashan,et al. Early detection and intervention in schizophrenia: research. , 1996, Schizophrenia bulletin.
[71] A. Yung,et al. The prodromal phase of first-episode psychosis: past and current conceptualizations. , 1996, Schizophrenia bulletin.
[72] J. Olney,et al. Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.
[73] Daniel R. Weinberger,et al. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground , 1995, Schizophrenia Research.
[74] Carol A. Tamminga,et al. Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.
[75] J. Lieberman,et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. , 1995, The American journal of psychiatry.
[76] J. Trojanowski,et al. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. , 1995, The American journal of psychiatry.
[77] E. G. Jones,et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. , 1995, Archives of general psychiatry.
[78] J. Ehrhardt,et al. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. , 1994, Science.
[79] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[80] Chantal Couture,et al. Mechanisms of action , 1994, Schizophrenia Research.
[81] P. Goldman-Rakic. Working memory dysfunction in schizophrenia. , 1994, The Journal of neuropsychiatry and clinical neurosciences.
[82] Philip D. Harvey,et al. Cognitive deficits in schizophrenia. , 1993, The Psychiatric clinics of North America.
[83] J. Lieberman,et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. , 1993, Archives of general psychiatry.
[84] K. Davis,et al. Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.
[85] D. Javitt,et al. Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.
[86] F. Vogel,et al. Schizophrenia genesis: The origins of madness , 1991 .
[87] B. Bunney,et al. Mechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia , 1991, Schizophrenia Research.
[88] F. Benes,et al. Reduced neuronal size in posterior hippocampus of schizophrenic patients. , 1991, Schizophrenia bulletin.
[89] B. Pakkenberg,et al. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. , 1990, Archives of general psychiatry.
[90] E. Walker,et al. Prediction of adult-onset schizophrenia from childhood home movies of the patients. , 1990, The American journal of psychiatry.
[91] S. Stone-Elander,et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.
[92] S. Hendry,et al. Activity-dependent regulation of GABA expression in the visual cortex of adult monkeys , 1988, Neuron.
[93] A Carlsson,et al. The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[94] M. Casanova,et al. Is there a neuropathology of schizophrenia? , 1988, Biological Psychiatry.
[95] G. Pearlson,et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. , 1986, Science.
[96] D. Weinberger,et al. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. , 1986, Archives of general psychiatry.